DELPhI Evaluation of Psychiatric Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03842345 |
Recruitment Status : Unknown
Verified February 2019 by QuantalX Neuroscience.
Recruitment status was: Not yet recruiting
First Posted : February 15, 2019
Last Update Posted : February 15, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Major Depressive Disorder Bi-Polar Disorder ADHD Schizophrenia OCD Ptsd Healthy |
Study Type : | Observational |
Estimated Enrollment : | 150 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Cross-sectional Evaluation of Psychiatric Population With DELPhI- Characterization of Psychiatric Conditions |
Estimated Study Start Date : | February 2019 |
Estimated Primary Completion Date : | February 2021 |
Estimated Study Completion Date : | February 2021 |

Group/Cohort |
---|
Psychiatric patients
Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
|
healthy controls
young healthy controls to serve as norm.
|
- comparison of DELPhI parameter of Plasticity in psychiatric population to healthy norms. [ Time Frame: through study completion, an average of 1 year ]Comparison of DELPhI parameters of Plasticity in patients, in comparison to healthy norms. Parameters will be analyzed for their temporal and special components.
- comparison of DELPhI parameter of Connectivity in psychiatric population to healthy norms. [ Time Frame: through study completion, an average of 1 year ]Comparison of DELPhI parameters of Connectivity in patients, in comparison to healthy norms. Parameters will be analyzed for their temporal and special components.
- correlation between DELPhI parameters and symptom severity. [ Time Frame: through study completion, an average of 1 year ]Self-control analysis of the change in DELPhI parameters following change in treatment prescription or any other treatment at different time points compared to base-line. Correlation to symptom severity will be assessed.
- Cluster analysis of Plasticity and connectivity in relation to medical treatment and clinical diagnosis. [ Time Frame: through study completion, an average of 1 year. ]Cluster subjects by each plasticity and connectivity vs. medical treatment and clinical diagnosis.
- characterization of the change in Plasticity following change of treatment regimen [ Time Frame: through study completion, an average of 1 year. ]characterization of the change in Plasticity of Plasticity following change of treatment regimen.
- characterization of the change in Connectivity following change of treatment regimen [ Time Frame: through study completion, an average of 1 year. ]characterization of the change in Connectivity following change of treatment regimen.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
study group: patients diagnosed with either Major depression, Bi-polar disorder, OCD, PTSD, ADHD or Schizophrenia,.without any psychiatric medications or with stable treatment regimen for the last 2 months.
Control group:
Eligible consecutive healthy individuals, recruited through advertisements spread in campuses and clinics.
Inclusion Criteria:
- Adult male and female patients between the age of 18-80 years old.
- Patients willing to participate with all of the study procedures and sign informed consent form.
- A clinical diagnosis of psychiatric condition that requires medication or other intervention (such as brain stimulation or psychological treatment).-study groups.
- Without any psychiatric medications or with stable treatment regimen for the last 2 months-study groups..
4.5. A normal neurological exam- control group.
Exclusion criteria:
1. Prior known epileptic episode. 2. History of any neurodegenerative disease. 3. Patients with history of other known brain disorder/pathology. 4. Contraindication to MR imaging.
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03842345
Contact: Iftach Dolev, PhD | +972-44659491 | doleviftach@gmail.com | |
Contact: Noa Zifman, MSc | +972-37553213 | noazif@gmail.com |
Responsible Party: | QuantalX Neuroscience |
ClinicalTrials.gov Identifier: | NCT03842345 |
Other Study ID Numbers: |
605 |
First Posted: | February 15, 2019 Key Record Dates |
Last Update Posted: | February 15, 2019 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Disease Schizophrenia Depressive Disorder Depressive Disorder, Major Bipolar Disorder |
Pathologic Processes Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Mood Disorders Bipolar and Related Disorders |